• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

Swiss Group Suggests Switzerland Use Compulsory Licences To Curb Cancer Drug Prices

24/05/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

During a side event held alongside this week’s World Health Assembly, public health advocates proposed that Switzerland use compulsory licensing as a way to decrease what they said are exorbitant drug prices.

Public Eye, a well-known Swiss non-governmental organisation, convened the side event at the 71th World Health Assembly, taking place from 21-26 May. On this occasion, they launched a new campaign: ‘For Affordable Drugs’.

According to Public Eye’s press release, the Swiss healthcare system is struggling to cope with the skyrocketing prices of new treatments, and in particular cancer drugs. Cancer treatments often reach over CHF 100,000 (US$100,000) per patient, per year, they said.

They suggest that Switzerland use compulsory licences, a mechanism allowed under the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which allow countries to produce generic medicines if they do not successfully negotiate lower prices with the patent holders.

Public Eye is supported by the Swiss Cancer League and is calling on Federal Councillors Berset and Schneider-Ammann “to take domestic and foreign policy measures to guarantee affordable drugs and to use compulsory licences whenever necessary.”

“Patents are one of the main causes of skyrocketing drug prices. Backed by a monopoly and market exclusivity, pharma companies can essentially set prices as they please,” the release said. “State control mechanisms are toothless when confronted to the pricing power of pharmaceutical companies.”

The NGO also published a paper on the issue of patents and prices: Protect patients, not patents [pdf].

They call on Switzerland to “unambiguously recognise compulsory licensing as legal, legitimate and effective tools. Resorting to this tool in a country where major pharmaceutical corporations are headquartered would ensure a sustainable healthcare system in Switzerland while sending a strong signal to the international community, motivating other countries to follow suit.”

“This would open the door to access to essential drugs for millions of people,” they said.

 

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

Catherine Saez may be reached at csaez@ip-watch.ch.

Creative Commons License"Swiss Group Suggests Switzerland Use Compulsory Licences To Curb Cancer Drug Prices" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: IP Policies, Language, Themes, Venues, English, Europe, Finance, Health & IP, Human Rights, Patents/Designs/Trade Secrets, Regional Policy, WHA 2018, WHO

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2022 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.